Stocks
Melinta Therapeutics IncMLNT
HealthcareBiotechnology
A biopharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Its lead product, Vabomere, targets multidrug-resistant gram-negative pathogens, and the company has faced financial restructuring while seeking regulatory approvals for additional indications. Investors track it for its pipeline in the infectious disease space and its potential for commercialization partnerships.
Congressional Interest in Melinta Therapeutics Inc (MLNT)
1 member of Congress has disclosed 1 trade in Melinta Therapeutics Inc (MLNT), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading MLNT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-02-26 | MICHAEL T. MCCAUL | sell | $1K-$15K |